SYShi-Xing Ye

Shi-Xing Ye

*This is an algorithmically generated author record based on publicly available information.

Shi-Xing Ye has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Hui Zhou

    Department of Pathology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Li-Yun Gong

    Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, Health Science Center, Shenzhen University, Shenzhen, P. R. China

    1 shared publication
  • Liping Ye

    Department of Breast and Thyroid Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, PR China

    1 shared publication
  • Xin-Yin Zhang

    Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China

    1 shared publication
  • Xin-Yu Xu

    Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China

    1 shared publication
  • Yan Li

    Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China

    1 shared publication

Latest Publications

  • Open Access

    Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival

    by Chun-Hui Zhou, Li-Ping Ye, Shi-Xing Ye, Yan Li, Xin-Yin Zhang, Xin-Yu Xu, Li-Yun Gong

    Background: Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC. Methods: SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations. Results: SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P = 0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P < 0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC. Conclusions: This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.